Press Releases

BioMS Medical Provides Multiple Sclerosis Trial Update

- Dr. Mark Freedman announced as Lead Investigator -

Edmonton, Alberta, October 26, 2004 – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Dr. Mark Freedman, Professor of Neurology at the University of Ottawa and Director of the Multiple Sclerosis Research Clinic at the Ottawa Hospital, as lead investigator for the Company's pivotal Phase II/III clinical trial of its lead drug MBP8298.

“I am pleased to play a key role in one of the only later-stage clinical trials assessing new therapies for secondary progressive multiple sclerosis, a form of the disease for which there are few approved therapies,” said Dr. Freedman. “This trial will assess the impact of this drug on disease progression and further our understanding of its underlying immunology.”

Dr. Freedman, B.Sc. M.Sc. M.D. CSPQ FAAN FRCPC, earned his medical degree at the University of Toronto, and performed post graduate training at the University of Toronto, Queen Square (London, UK), McGill and the Weizmann Institute of Science (Israel). He has published more than 100 papers, book chapters and reviews on MS. Dr. Freedman is also a Fellow of the American Academy of Neurology, serves on the medical advisory committee for the MS Society of Canada and is a member of the clinical trial group for the National MS Society (USA).

As Director of the Multiple Sclerosis Research Clinic at the Ottawa Hospital, he operates a large and successful MS research unit with approximately 3000 patients.
“The interest in our trial amongst other leading MS clinicians in Canada has been very positive, and enrollment of patients is targeted to commence soon at a number of sites,” said Kevin Giese, President of BioMS Medical. “Dr. Freedman's leadership role in our trial is supported by his past 20 years of experience in the clinical development of the current major MS therapies.”

The trial, approved by Health Canada on June 8, 2004, will enroll up to 553 patients and is designed to evaluate the efficacy and safety of MBP8298 in patients with secondary progressive MS. The Company also intends to seek regulatory approval for the trial outside of Canada to enroll patients on an international basis.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.